Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aldeyra Therapeu (NQ: ALDX )

5.350 -0.020 (-0.37%)
Streaming Delayed Price Updated: 10:03 AM EDT, Oct 14, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Aldeyra Therapeu

< Previous 1 2 3 4 5 Next >
Recap: Aldeyra Therapeutics Q1 Earnings
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
The Week In Charts: 0DTE Options - Too Good To Be True?
Zero-days; how Core Methodology can be used in Crypto, with current Crypto and stock market conditions; favorite stock picks. 
Via Talk Markets
Short Volatility Alert: Aldeyra Therapeutics
On Thursday, shares of Aldeyra Therapeutics (NASDAQ: ALDX) experienced volatile short activity. After the activity, the stock price went down -0.22% to $9.05. The overall sentiment for ALDX has been... 
Via Benzinga
OKYO Pharma Management Takes Company Stock In Private Placement Instead Of Deferred Pay
Drug development can be notoriously slow, and it can take some companies 10 years or more to pass through all the trials and tests required by the Food and Drug Administration (FDA). 
Via Benzinga
Chart Of The Day: Aldeyra - Skyrocketing
Revenue is expected to grow by 2,045.80% next year. Earnings are estimated to increase by 16.90% next year and continue to compound at an annual rate of 73.70% for the next 5 years. 
Via Talk Markets
Earnings Outlook For Aldeyra Therapeutics
Via Benzinga
Aldeyra's ADX-2191 Aces Late-Stage Study In Rare Vision Disorder
Via Benzinga
Recap: Aldeyra Therapeutics Q2 Earnings
  Aldeyra Therapeutics (NASDAQ:ALDX) reported its Q2 earnings results on Friday, August 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
OKYO Pharma To Begin Phase 2 Efficacy Trials For Dry Eye Disease Drug Candidate In March 2023, Anticipates Releasing Topline Results By Q4
Drug development isn’t known for being fast-paced, and developing any new drug is generally a long process. However, OKYO Pharma Ltd. (NASDAQ: OKYO) is moving quickly to develop its eye treatment drug,... 
Via Benzinga
BioNTech, Coinbase Global, Pharming Group And Other Big Stocks Moving Lower On Monday
U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
UBS, Credit Suisse And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
KB Home, Accenture, Netflix And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Aldeyra's Reproxalap Hits Primary Goals In Dry Eye Disease Chamber Crossover Trial
Via Benzinga
Why Aldeyra Therapeutics' Shares Are Soaring Today?
Via Benzinga
Aldeyra Highlights 12-Month Safety Data Of Reproxalap In Dry Eye Disease Patients
Via Benzinga
Bio-Pharma Company OKYO Pharma Tackles A Common Eye Disease For Which The Current Treatments Aren't Effective Enough
An eye condition that has been described as a stealth disease currently affects as many as 49 million Americans. Dry Eye Disease (DED) afflicts over one-third of Americans over 50 and... 
Via Benzinga
Aldeyra Therapeutics' RASP Modulator Shows Improved Signs of Alcohol Intoxication
Via Benzinga
Important Biotech Catalysts For September 14, 2022 - End Of The Day Summary
Via Benzinga
$2 Million Bet On This Industrial Stock? 4 Stocks Insiders Are Buying
Although US stocks closed mixed on Friday, there were a few notable insider trades. 
Via Benzinga
Aldeyra Therapeutics: Q1 Earnings Insights
Aldeyra Therapeutics (NASDAQ:ALDX) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Earnings Scheduled For August 5, 2022
Companies Reporting Before The Bell • Reservoir Media (NASDAQ:RSVR) is projected to report quarterly loss at $0.05 per share on revenue of $18.19 million. 
Via Benzinga
Earnings Outlook For Aldeyra Therapeutics
Aldeyra Therapeutics (NASDAQ:ALDX) is set to give its latest quarterly earnings report on Friday, 2022-08-05. Here's what investors need to know before the announcement. Analysts estimate that Aldeyra... 
Via Benzinga
Boeing, PriceSmart And 80 Biggest Movers From Yesterday
Gainers Sharps Compliance Corp. (NASDAQ: SMED) shares jumped 196.1% to close at $8.44 on Tuesday after the company it will be acquired by an affiliate of Aurora Capital Partners for $8.75 per share. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
  
Via Benzinga
The Daily Biotech Pulse: GSK To Supply 50M Flu Vaccine Doses To US, FDA Lifts Hold On Greenwich's Cancer Immunotherapy Trial, Connect Biopharma Sees CBP-201 Topline Data Sooner
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
  
Via Benzinga
Aldeyra's Dry Eye Candidate Tops Vehicle In Post-Hoc Analysis Using Computer Automated Grading In Ocular Redness
Via Benzinga
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.